+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer



Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer



Clinical Cancer Research 8(11): 3394-3400



We have previously reported (K. Kono et al., Int. J. Cancer, 78: 202-208, 1998) that HER-2/neu-derived peptides are naturally processed as tumor-associated antigens recognized by tumor-specific, human leukocyte antigen (HLA)-A2-restricted CTLs in gastric cancer. In the present study, we described a Phase-1 vaccination trial in gastric cancer patients using dendritic cells (DCs) pulsed with the immunodominant HER-2/neu(p369) peptides. Nine enrolled patients, who had HER-2/neu-overexpressing tumors and who were HLA-A2 positive, received four vaccinations by DCs pulsed with HER-2(p369) peptide at 2-week intervals intradermally. There were no serious adverse effects noted in the immunized patients. Peripheral blood mononuclear cells, preimmunization and after the fourth immunization, were cultured with autologous, HER-2(p369)-pulsed antigen-presenting cells for 12 days. Thereafter, peptide specificity was evaluated by IFN-gamma secretion assay from cultured T cells against T2 cells pulsed with HER-2(p369) peptide. HER-2/neu peptide-specific recognition could be demonstrated in six of nine patients after immunization, whereas there was no HER-2/neu peptide-specific recognition before immunization. The peptide-specific CTL lines isolated from two of the patients could also lyse a HER2/neu-transfected cell line. Furthermore, a peptide-specific delayed-type hypersensitivity response occurred in three of nine patients. One of the patients underwent a partial clinical response concurrent with a decrease of tumor marker. Another patient demonstrated a stabilization of disease status for a period of 3 months. Taken together, tumor vaccination therapy with DCs pulsed with HER-2/neu-peptides may be a potential candidate for the novel treatment of gastric cancer patients.

(PDF emailed within 1 workday: $29.90)

Accession: 045724226

Download citation: RISBibTeXText

PMID: 12429626


Related references

Monitoring of prostate-specific membrane antigen -restricted responses in patients treated with dendritic cells pulsed with PSMA-derived peptides. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 616, 1997

Monitoring of prostate-specific membrane antigen- specific immune responses and prostate markers in a phase II clinical trial with patients infused with dendritic cells pulsed with PSMA-derived peptides. Proceedings of the American Association for Cancer Research Annual Meeting 39: 173, 1998

Demonstration of in vivo and in vivo immune responses in a phase II clinical trial following infusion of dendritic cells pulsed with prostate-specific membrane antigen- derived peptides into patients with early and advanced prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 40: 409, 1999

Whole tumor cell lysate pulsed dendritic cells induce the immune responses of autologous T lymphocytes from breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting (41): 519, 2000

Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients. Leukemia Research 32(11): 1653-1660, 2008

Dendritic cells pulsed with hsp70-peptide complexes derived from human hepatocellular carcinoma induce specific anti-tumor immune responses. World Journal of Gastroenterology 11(36): 5614-5620, 2005

Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses. Cancer Immunology, ImmunoTherapy 52(7): 413-422, 2003

Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clinical and Experimental Immunology 147(2): 277-286, 2007

A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clinical and Experimental Immunology 153(3): 392-400, 2008

Immune enhancement in a phase II clinical trial following infusion of dendritic cells pulsed with prostate-specific membrane antigen- derived peptides into prostate cancer patients. FASEB Journal 13(4 PART 1): A301, March 12, 1999

Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Science 100(8): 1502-1509, 2009

Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35(2): 144-151, 1998

Bone marrow-derived dendritic cells pulsed with tumor lysates induce anti-tumor immunity against gastric cancer ex vivo. World Journal of Gastroenterology 14(46): 7127-7132, 2009

NK-like T-lymphocytes and dendritic cells pulsed with pancreatic cancer tumor cell lines derived RNA are effective to induce cytolytic activity against pancreatic cancer. Gastroenterology 118(4 Suppl 2 Part 1): AGA A528, 2000

Dendritic cells derived from hematopoietic stem cells pulsed with p53 induce a specific immune response against HMCC97 hepatocellular carcinoma cells. Beijing Da Xue Xue Bao. Yi Xue Ban 40(5): 489-493, 2008